Institutional Ownership
Trevi Therapeutics Inc
CUSIP 89532M101COMTRVIQ1 2026
13D / 13G Filings
55
Schedule 13D/13G on record
Beneficial Filers
16
Distinct reporting persons
Largest Stake
42.5%
Max % of class reported
Institutional Holders
191
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
55 filings · latest Feb 13, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 13, 2026 | Rubric Capital Management LP | 13G/A | 2.9% | 3.77M | SEC |
| 2 | Feb 13, 2026 | New Enterprise Associates 16, L.P. | 13D/A | 11.6% | — | SEC |
| 3 | Feb 5, 2026 | Fmr LLC | 13G | 5.1% | 6.50M | SEC |
| 4 | Jan 30, 2026 | The Vanguard Group | 13G | 5.0% | 6.43M | SEC |
| 5 | Nov 14, 2025 | Frazier Life Sciences Public Fund, L.P. | 13G/A | 7.0% | 8.51M | SEC |
| 6 | Nov 14, 2025 | Viking Global Investors LP | 13G/A | 4.2% | 5.13M | SEC |
| 7 | Oct 17, 2025 | Blackrock, Inc. | 13G | 5.6% | 6.80M | SEC |
| 8 | Aug 14, 2025 | Viking Global Investors LP | 13G/A | 5.9% | 7.51M | SEC |
| 9 | Aug 11, 2025 | New Enterprise Associates 16, L.P. | 13D/A | 12.0% | — | SEC |
| 10 | Jul 9, 2025 | Rubric Capital Management LP | 13G | 7.1% | 8.53M | SEC |
45 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Trevi Therapeutics Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Nea Management Company, LLC | 13.22M | $157.74M |
| 2 | Blackrock, Inc. | 10.24M | $122.17M |
| 3 | Frazier Life Sciences Management, L.P. | 9.94M | $118.58M |
| 4 | Fmr LLC | 8.04M | $95.89M |
| 5 | Wellington Management Group LLP | 5.19M | $61.91M |
| 6 | Vivo Capital, LLC | 5.09M | $60.78M |
| 7 | Marshall Wace, LLP | 3.97M | $47.31M |
| 8 | Rubric Capital Management LP | 3.71M | $44.29M |
| 9 | Mpm Bioimpact LLC | 3.30M | $39.35M |
| 10 | Viking Global Investors LP | 3.20M | $38.16M |